Ignite Creation Date:
2024-05-06 @ 12:33 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03792568
Status:
UNKNOWN
Last Update Posted:
2019-02-15
First Post:
2019-01-02
Brief Title:
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation
Sponsor:
Shanghai Changzheng Hospital
Organization:
Shanghai Changzheng Hospital
Study Overview
Official Title:
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation
Status:
UNKNOWN
Status Verified Date:
2019-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial aims to evaluate the efficacy safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None